Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Fig. 7

Leronlimab significantly increases survival in mice with established breast cancer lung metastasis. a Schematic representation of the study design. The mice were injected with MDA-MB-231-pFULG cells via the tail vein. After 7 weeks, when breast cancer lung metastasis was established, the mice were randomly assigned into two cohorts. One cohort was treated with leronlimab (2 mg/mouse, twice a week, 8 mice), and the other was as untreated control. b The survival of mice is plotted with time after the addition of treatment from week 7. c Representative examples of the tumor volume for mice treated with leronlimab, plotted with time after the addition of treatment from week 7. In five mice, the tumor volume decreased as shown (#1, #2, #3, #7, and #8. Mouse #3 was dead between 13 and 14 weeks due to fighting). The decrease in tumor size in mouse #1 was 3-fold to 0.1-fold; #2, 1.2-fold to 0.01-fold; #3, 14.4-fold to 3.7-fold; #7, 7-fold to 0.9-fold; and #8 35.9-fold to 4.7-fold)

Back to article page
\